- Home
- AQB vs RDHL Comparison
AQB vs RDHL Comparison
Compare AQB & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AQB | RDHL |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.8M |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | AQB | RDHL |
|---|---|---|
| Price | $1.00 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.9K | ★ 19.3K |
| Earning Date | 05-14-2026 | 11-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.66 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,472,659.00 | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.60 | $0.71 |
| 52 Week High | $2.95 | $3.31 |
Technical Indicators
Market Signals| Indicator | AQB | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 44.41 |
| Support Level | $0.86 | $0.80 |
| Resistance Level | $1.00 | $0.90 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 82.56 | 61.12 |
Price Performance
Historical ComparisonAbout AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.